David Scott Jones Eye Point Pharmaceuticals, Inc. (EYPT) insider trading activity

David Scott Jones is SVP & Chief Commercial Officer of EyePoint Pharmaceuticals, Inc.. Currently has a direct ownership of 44,916 shares of EYPT, which is worth approximately $390,769. The most recent transaction as insider was on Feb 09, 2024, when has been sold 3,656 shares (Common Stock) at a price of $28.8 per share, resulting in proceeds of $105,292. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 44.9K

0% 3M change

78.71% 12M change

Total Value Held $390,769

David Scott Jones Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 09 2024	SELL Payment of exercise price or tax liability	$105,292 $28.8 p/Share	3,656 Reduced 7.53%	44,916 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	9,967 Added 17.03%	48,572 Common Stock
Feb 02 2024	SELL Open market or private sale	$5,954 $28.49 p/Share	209 Reduced 0.55%	37,962 Common Stock
Feb 02 2024	BUY Exercise of conversion of derivative security	$2,397 $11.47 p/Share	209 Added 0.54%	38,171 Common Stock
Jan 26 2024	SELL Open market or private sale	$659,791 $25.36 p/Share	26,017 Reduced 40.66%	37,962 Common Stock
Jan 26 2024	BUY Exercise of conversion of derivative security	$210,217 $8.08 p/Share	26,017 Added 28.91%	63,979 Common Stock
Jan 25 2024	SELL Open market or private sale	$15,000 $25.0 p/Share	600 Reduced 1.56%	37,962 Common Stock

Jan 25 2024	BUY Exercise of conversion of derivative security	$4,848 $8.08 p/Share	600 Added 1.53%	38,562 Common Stock
Jan 24 2024	SELL Open market or private sale	$282,613 $25.01 p/Share	11,300 Reduced 22.94%	37,962 Common Stock
Jan 24 2024	BUY Exercise of conversion of derivative security	$91,304 $8.08 p/Share	11,300 Added 18.66%	49,262 Common Stock
Jan 23 2024	SELL Open market or private sale	$22,500 $25.0 p/Share	900 Reduced 2.32%	37,962 Common Stock
Jan 23 2024	BUY Exercise of conversion of derivative security	$7,272 $8.08 p/Share	900 Added 2.26%	38,862 Common Stock
Jan 22 2024	SELL Open market or private sale	$767,710 $22.47 p/Share	34,166 Reduced 47.37%	37,962 Common Stock
Jan 22 2024	BUY Exercise of conversion of derivative security	$368,992 $10.8 p/Share	34,166 Added 32.14%	72,128 Common Stock
Jan 06 2024	SELL Payment of exercise price or tax liability	$84,598 $20.4 p/Share	4,147 Reduced 9.85%	37,962 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	15,285 Added 26.63%	42,109 Common Stock
Feb 09 2023	SELL Payment of exercise price or tax liability	$12,326 $4.17 p/Share	2,956 Reduced 10.52%	25,133 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	-	9,967 Added 26.19%	28,089 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$11,243 $9.95 p/Share	1,130 Reduced 6.75%	15,599 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	-	4,105 Added 19.7%	16,729 Common Stock
Feb 09 2022	SELL Payment of exercise price or tax liability	$14,921 $10.13 p/Share	1,473 Reduced 10.45%	12,624 Common Stock
Feb 09 2022	BUY Exercise of conversion of derivative security	-	4,966 Added 26.05%	14,097 Common Stock
Feb 28 2021	SELL Payment of exercise price or tax liability	$18,399 $10.81 p/Share	1,702 Reduced 18.74%	7,380 Common Stock
Feb 28 2021	BUY Exercise of conversion of derivative security	-	4,105 Added 31.13%	9,082 Common Stock

DSJ

David Scott Jones

SVP & Chief Commercial Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EYPT shares.

Notify only if

Value

Insider Trading

Get notified when an Eye Point Pharmaceuticals, Inc. insider buys or sells EYPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to EyePoint Pharmaceuticals, Inc.

Track Activities on EYPT

Account